The hepatitis C protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV-positive people with genotype 1 hepatitis C co-infection in the STARTVerso4 trial, according to a poster presented at The Liver Meeting 2013 , the 64th annual meeting of the American Association for the Study of ... (more)
http://www.aidsmap.com/page/2803165/
http://www.aidsmap.com/page/2803165/
No comments:
Post a Comment